Key Takeaways
- • Trilantic North America's exit from SOFIE Biosciences is valued at $945 million, according to the headline, and is attributed in part to a boom in radiopharmaceuticals.
- • Apollo, Kohlberg, and Montagu are pursuing surgical equipment providers, per PE Hub's coverage.
- • PE Hub argues that barriers to entry make sectors more attractive to private equity firms that already have a sizeable presence in them.
- • The analysis covers two healthcare markets: surgical equipment providers and radiopharmaceuticals.
Summary
PE Hub reports that Apollo, Kohlberg, and Montagu are pursuing surgical equipment providers, while the radiopharmaceutical sector's growth has supported Trilantic North America's $945 million exit from SOFIE Biosciences. The coverage frames the two developments around a common theme: barriers to entry make sectors more attractive to private equity firms that already have a substantial presence in them.
The piece examines how this dynamic plays out in two healthcare markets. In surgical equipment, the firms named in the headline are pursuing providers. In radiopharmaceuticals, the strength of the sector has contributed to the value realized in Trilantic North America's sale of SOFIE Biosciences, a radiopharmaceutical company.
The available source material is limited to the headline and publisher summary, so the article's specific deal terms, buyers, and valuation methodology cannot be confirmed here.
The piece examines how this dynamic plays out in two healthcare markets. In surgical equipment, the firms named in the headline are pursuing providers. In radiopharmaceuticals, the strength of the sector has contributed to the value realized in Trilantic North America's sale of SOFIE Biosciences, a radiopharmaceutical company.
The available source material is limited to the headline and publisher summary, so the article's specific deal terms, buyers, and valuation methodology cannot be confirmed here.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.